PolyPid Ltd. (PYPD) News

PolyPid Ltd. (PYPD): $3.38

0.11 (-3.15%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

Add PYPD to Watchlist
Sign Up

Filter PYPD News Items

PYPD News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest PYPD News From Around the Web

Below are the latest news stories about POLYPID LTD that investors may wish to consider to help them evaluate PYPD as an investment opportunity.

PolyPid Ltd. (NASDAQ:PYPD) Q3 2023 Earnings Call Transcript

PolyPid Ltd. (NASDAQ:PYPD) Q3 2023 Earnings Call Transcript November 12, 2023 Operator: Thank you all for participating in PolyPid’s third quarter 2023 earnings conference call. Joining me on the call today will be Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid; Jonny Missulawin, PolyPid’s Chief Financial Officer; and Ori Warshavsky, Chief Operating Officer of PolyPid. […]

Yahoo | November 12, 2023

PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Total of 20 Centers Currently Open with Approximately 40 Expected by End of 2023 in SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Completed Production and Release of Three Process Validation Batches of D-PLEX100 Successful Completion of Good Manufacturing Practice Audit of Company’s Manufacturing Facility Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Nov. 08, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq

Yahoo | November 8, 2023

PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors

Biopharmaceutical Industry Veteran Nurit Tweezer-Zaks, M.D., M.B.A. Appointed to Board Following Retirement of Anat Tsour SegalPETACH TIKVA, Israel, Nov. 07, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Nurit Tweezer-Zaks, M.D., M.B.A, to its Board of Directors, effective November 6, 2023, following the retirement of Anat Tsour Segal. Dr. Tweezer-Zaks is a

Yahoo | November 7, 2023

PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023

PETACH TIKVA, Israel, Nov. 01, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 8, 2023. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business ope

Yahoo | November 1, 2023

PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

PETACH TIKVA, Israel, Oct. 11, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a written notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities, including the Company's ordinary shares

Yahoo | October 11, 2023

PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023

PETACH TIKVA, Israel, Oct. 09, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that SHIELD I Phase 3 clinical data for D-PLEX100 will be highlighted in a presentation at the American College of Surgeons Clinical Congress 2023, to be held on October 22-25, 2023, in Boston, MA. American College of Surgeons Clinical Congress 2023 Presentation Title: Impact of Locally Applied Doxycy

Yahoo | October 9, 2023

PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology Platform

Safety Profile of D-PLEX100 and PLEX Platform Shown in Juvenile Animals for the First Time Results Could Support Clinical Evaluation of D-PLEX100 in Pediatric Population PETACH TIKVA, Israel, Oct. 04, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the publication of positive preclinical results demonstrating, for the first time, the safety profile of D-PLEX100 and the PLEX tech

Yahoo | October 4, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are worth keeping track of and we're helping with the biggest winners and losers for Wednesday morning!

William White on InvestorPlace | September 27, 2023

PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

PETACH TIKVA, Israel, Sept. 22, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company’s management will present at the Cantor Global Healthcare Conference taking place on September 26-28, 2023, in New York City, New York. Cantor Global Healthcare Conference: Presentation Date: Thursday, September 28, 2023Presentation Time:8:00 AM Eastern Time The PolyPid management team

Yahoo | September 22, 2023

PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health

Successful Audit of the Company’s State-of-the-Art Manufacturing Facility Represents a Key Milestone Toward Plan to Commercialize D-PLEX₁₀₀ GloballyPETACH TIKVA, Israel, Sept. 21, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Israeli Ministry of Health has completed a successful Good Manufacturing Practice (GMP) audit of the Company's manufacturing facility without an

Yahoo | September 21, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!